Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Zongertinib

Drug class: Kinase Inhibitor

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Zongertinib used for?
The FDA-approved label (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc., August 13, 2026) says: “HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test […]. This indication is approved under accelerated approval based on objective response rate and duration of response […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Zongertinib have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Zongertinib?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Zongertinib been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Zongertinib?
1 company lists prescription products of Zongertinib in the FDA NDC Directory, including Boehringer Ingelheim Pharmaceuticals, Inc..

What Zongertinib is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test […]. This indication is approved under accelerated approval based on objective response rate and duration of response […]. …

— FDA label: Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc., effective August 13, 2026. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Forms and how it is given

Dosage formsTablet, film coated
RouteOral
Prescription products1 in the FDA NDC Directory
Brand namesHernexeos

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA219042
HERNEXEOS
Boehringer IngelheimAugust 8, 2025 3, latest July 31, 2026
2026: Labeling · 2026: Labeling · 2026: Efficacy

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2721609, 2721615
SPL set ID of the quoted labeld3fabf12-354e-4e5c-b5de-20fdb579b783
FDA labels (SPL)1
FDA applicationsNDA219042
Active ingredients (FDA)ZONGERTINIB

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc., effective August 13, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers